GE HealthCare announces cash dividend for second quarter of 2026
GE HealthCare introduces Allia upgrade pathways designed to modernize existing interventional suites
GE HealthCare advancing enterprise imaging with cloud-enabled solutions
GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities
ESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions
GE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact
GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth
GE HealthCare reports first quarter 2026 financial results
GE HealthCare management to present at upcoming investor conferences
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
